Stemgent StainAlive TRA-1-60 Antibody (DyLight 488), Mouse anti-Human

THIS PRODUCT HAS BEEN DISCONTINUED.  

The TRA-1-60 antibody reacts with a pluripotent, stem cell-specific antigen expressed on undifferentiated human embryonic stem (ES) cells, embryonal carcinoma (EC) cells, and embryonic germ (EG) cells. The expression of TRA-1-60 on human ES cells is down-regulated upon differentiation. The TRA-1-60 antibody recognizes a neuraminidase-resistant carbohydrate epitope expressed on podocalyxin, a member of the CD34-related family of sialomucins. Podocalyxin is a transmembrane glycoprotein, which has been implicated in the development of aggressiveness in a variety of cancers

This antibody is ideal for live-staining cells because it has been specifically formulated with low endotoxin and no sodium azide. This allows in-process monitoring of reprogramming experiments without sacrificing cells. ES cell morphology, proliferation, and expression of pluripotency markers does not change after staining with StainAlive TRA-1-60 antibody.

Immunocytochemical analysis of TRA-1-60 on H1 human ES cells. Phase contrast view of cells in culture and the same field of view after staining with StainAlive TRA-1-60 Antibody (DyLight 488) using a 1:100 dilution.

Product Name

StainAlive TRA-1-60 Antibody (DyLight 488), Mouse anti-Human

Catalog Number

09-0068

Size

100 µL

Formulation

Phosphate-buffered solution, pH 7.2, containing no preservative

Storage and Stability

Store at 4 °C protected from light. Do not freeze. Handle under aseptic conditions. Stable for 6 months from date of receipt when stored as directed.

Quality Control

Tested by immunocytochemistry to ensure product quality. Endotoxin level is less than 0.1 EU/µg (0.01 ng/µg) of the protein as determined by the LAL assay.

Recommended Usage

The suggested use of this antibody is a 1:100 dilution for immunocytochemistry. For an application specific protocol, please see General Protocol for ICC Staining of Live Cells.

Concentration

0.5 mg/mL

Isotype

Mouse IgM, κ

Immunogen

Human embryonal carcinoma (EC) cell line 2102Ep

Reactivity

Human

Preparation

This antibody was purified by affinity chromatography and conjugated with DyLight 488 under optimal conditions. The solution is free of unconjugated dye and unlabeled antibody. 0.2 µm filter sterilized.

Formulation

Free from bacteria, fungi, mycoplasma, and mouse virus.

Clone

TRA-1-60

Specification Sheets

• 09-0068 Specifications Sheet

Safety Data Sheets

• 09-0068 Safety Data Sheet

Protocols

• General Protocol for ICC Staining of Live Cells

1. Takahashi, K., Tanabe K., Ohnuki, M., Narita, M., Ichisaka T., Tomoda K. and Yamanaka, S. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
2. Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, I.I., and Thomson, J.A. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
3. Schopperle, W.M., and DeWolf, W.C. (2007) The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells 25: 723-730.
4. Chin, A.C., Fong, W.J., Goh, L.T., Philp, R., Oh, S.K., and Choo, A.B. (2007) Identification of proteins from feeder conditioned medium that support human embryonic stem cells. J Biotechnol 130: 320-328.
5. Badcock, G., Pigott, C., Goepel, J., and Andrews, P.W. (1999) The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratan sulfate proteoglycan. Cancer Res 59: 4715-4719.
6. Andrews, P.W., Banting, G., Damjanov, I., Arnaud, D., and Avner, P. (1984) Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 3: 347-361.

Additional Publications

• Supakul S; Leventoux N; Tabuchi J; Mimura M; Ito D; Maeda S; Okano H. Establishment of KEIOi005-A iPSC line from urine-derived cells (UDCs) of a mild Alzheimer’s disease (AD) donor with multiple risk SNPs for sporadic Alzheimer’s disease (sAD). Stem Cell Res 62:102802 (2022).
• Woods S; Bates N; Dunn SL; Serracino-Inglott F; Hardingham TE; Kimber SJ. Generation of Human Induced Pluripotent Stem Cells from Anterior Cruciate Ligament. J Orthopedic Res in press:doi: 10.1002/jor.24493 (2019).
• Malerba n; Benzoni P; Squeo GM; Milanesi R; Giannetti F; Sadleir LG; Poke G; Augello B; Croce AI; Barbuti A; Merla G. Generation of the induced human pluripotent stem cell lines CSSi009-A from a patient with GNB5 pathogenic variant, and CSSi010-A from a CRISPR/Cas9 engineered GNB5 knock-out human cell line. Stem Cell Research in press:e192635 (2019).
• Takahashi M; Yamazaki S. Generation of a human induced pluripotent stem cell line, IMSUTi002-A-1, harboring the leukemia-specific fusion gene ETV6-RUNX1. Stem Cell Research 40: (2019).
• Hsieh W-C; Ramadesikan S; Fekete D; Aguilar RC. Kidney-differentiated cells derived from Lowe Syndrome patient’s iPSCs show ciliogenesis defects and Six2 retention at the Golgi complex. PLoS ONE 13:120 (2018)
• Gagliano O; Luni C; Qui W; Bertin E; Torchio E; Galvanin S; Urciuolo A; Elvassore N. Microfluidic reprogramming to pluripotency of human somatic cells. Nat. Protocols 14:772-737 (2019).
• Sridhar A; Ohlemacher SK; Langer KB; Meyer JS. Robust differentiation of mRNA-reprogrammed human induced pluripotent stem cells toward a retinal lineage. Stem Cell Translational Medicine 5:417 (2016)
• Ohlemacher SK; Sridhar A; Xiao Y; Hochstetler AE; Sarfarazi M; Cummins TR; Meyer JS. "Stepwise differentiation of retinal ganglion cells from human pluripotent stem cells enables analysis of glaucomatous neurodegeneration. Stem Cells doi: 10.1002/stem.2356 (2016)
• Poleganov MA; Eminli S; Beissert T; Herz S; Moon J-I; Goldmann J; Beyer A; Heck R; Burkhart I; Roldan DB; Tureci O; Yi K; Hamilton B; Sahin U. Efficient reprogramming of human fibroblasts and blood-derived endothelial progenitor cells using nonmodified RNA for reprogramming and immune evasion. Human Gene Therapy 26:751 (2015)
• Briggs SF; Dominguez AA; Chavez SL; Reijo Pera RA. XIST in human preimplantation embryos and iPSCs. Stem Cells 33:1771 (2015)
• Wang J; Huang V; Ye L; Barcena A; Lin G; Lue TF; Li L-C. Identification of small activating RNAs that enhance endogenous OCT4 expression in human mesenchymal stem cells. Stem Cells Develop 24:345 (2015)
• Haraguchi Y; Matsuura K; Shimizu T; Yamato M; Okano T. Simple suspension culture system of human iPS cells maintianting the pluripotency for cardiac cell sheet engineering. J Tissue Eng Regen Medicine 9:1363 (2015)
• Rajasingh S; Thangavel J; Czirok A; Samanta S. Generation of functional cardiomyocytes from efficiently generated human iPSCs and a novel method for measuring contractility. PLoS one (2015)
• Pollen AA; Nowakowski TJ; Shuga J; Wang X; Leyrat AA; Lui JH; Li Z; Szpankowski L; Fowler B; Chen P; Ramalingam N; Sun G; Thu M; Norris M; Lebofsky R; Toppani D; Kemp DW; Wong M; Clerkson B; Jones BN; Wu S; Knutsson L; Alvaredo B; Wang J; Weaver LS; May AP; Jones RC; Unger MA; Kriegtein AR. Low-coverage single-cell mRNA sequencing reveals cellular heterogeneity and activated signaling pathways in developing cerebral cortex. Nature Biotechnology 32:1053 (2014)
• Tan H-K; Toh C-XDl Ma D; Yang B; Liu TM; Lu J; Wong C-W; Tan T-K; Li H; SYn C; Tan E-L; Lim B; Lim Y-P; Cook SA; Loh Y-H. Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. Stem Cells Trans Medicine 3:586 (2014)